Connect with us


Bioasis Technologies’ xB3 Platform Unlocks Revolutionary Neurological Disease Treatments

The blood-brain barrier is a major hurdle in treating a whole range of diseases affecting the CNS. While it serves a vital role in protecting against blood-borne pathogens, it also prevents the delivery of many pharmaceutical drugs. Now, an innovation from Bioasis Technologies Inc. is set to overcome this obstacle, unlocking new treatment vectors for brain cancer and neurodegenerative diseases.



This biotech trailblazer is giving hope to patients suffering from neurological disease
Dr. Mei Mei Tian, Vice President, Head of External Research, discusses the unmet need when it comes to successfully targeting central nervous system disorders as well as delivering medicine directly to the brain — and how Bioasis’ technology could help.

Dr. Mei Mei Tian:

Treatment of diseases and disorders affecting the central nervous system is a significant area of unmet need in global health. One of the critical factors affecting the success of development programs targeting treatments for CNS disorders is the challenges with delivery of drugs into the brain across the blood-brain barrier.

Bioasis’ proprietary xB3 platform technology acts as a brain delivery vector, transforming either existing or novel non-brain penetrating therapeutics into new, more efficacious agents that are able to also cross the blood-brain barrier to engage targets in the brain. 

We have demonstrated success in various preclinical disease models in the areas of brain cancer and neurodegenerative diseases, both through internal R&D and external validating partnerships.

At Bioasis, we are actively and continuously developing our xB3 platform technology to overcome the challenges of drug brain delivery, especially in the area of rare diseases.

About Bioasis Technologies Inc.:

Bioasis Technologies Inc. (TSXV: BTI | OTCQB: BIOAF) is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.


(Featured image by Oksana Krasyuk via Adobe Stock)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Born2Invest, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

Angelique Moss is a London-based entrepreneur, writer, and traveller. The world of business, finance, and technology, is her preferred cup of tea. She also writes about the developments and discussions on health, art, luxury and media. A top writer for several Medium publications, she has published hundreds of widely read articles on investing, stocks, global markets, cannabis, and technology for multiple platforms. She is also interested in culture, history, and social affairs.